000157349 001__ 157349
000157349 005__ 20240229123135.0
000157349 0247_ $$2doi$$a10.1016/j.jtauto.2020.100058
000157349 0247_ $$2pmid$$apmid:32743538
000157349 0247_ $$2pmc$$apmc:PMC7388361
000157349 0247_ $$2altmetric$$aaltmetric:87130044
000157349 037__ $$aDKFZ-2020-01578
000157349 041__ $$aeng
000157349 082__ $$a610
000157349 1001_ $$0P:(DE-He78)9af7dea9c075a972fcfa22b583471dae$$aThomsen, Hauke$$b0$$eFirst author
000157349 245__ $$aFamilial risks between Graves disease and Hashimoto thyroiditis and other autoimmune diseases in the population of Sweden.
000157349 260__ $$aAmsterdam$$bElsevier$$c2020
000157349 3367_ $$2DRIVER$$aarticle
000157349 3367_ $$2DataCite$$aOutput Types/Journal article
000157349 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1692365263_10946
000157349 3367_ $$2BibTeX$$aARTICLE
000157349 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157349 3367_ $$00$$2EndNote$$aJournal Article
000157349 500__ $$aJournal of Translational Autoimmunity (Journal of Translational Autoimmunity) = 2589-9090 (import from CrossRef, PubMed, )#EA:C050#LA:C050#
000157349 520__ $$aGenetic and family studies have indicated that Graves disease and Hashimoto thyroiditis have a heritable component which appears to be shared to some extend also with some other autoimmune diseases (AIDs). In the present nation-wide study we describe familial risk for Graves disease and Hashimoto thyroiditis identified from the Swedish Hospital Discharge Register (years 1964 through 2012) and the Outpatient Register (2001 through 2012). Family relationships were obtained from the Multigeneration Register and cancers from the Cancer Registry. Familial standardized incidence ratios (SIRs) were calculated for 29,005 offspring with Graves disease and for 25,607 offspring with Hashimoto thyroiditis depending on any of 43 AIDs in parents or siblings. The concordant familial risks for Graves disease and Hashimoto thyroiditis were 3.85 and 4.75, higher for men than for women. The familial risks were very high (11.35, Graves and 22.06, Hashimoto) when both a parent and a sibling were affected. Spousal familial risks were higher for Hashimoto thyroiditis (1.98/1.93) than for Graves disease (1.48/1.50). For Graves disease, 24 discordant AIDs showed a significant association; for Hashimoto thyroiditis, 20 discordant associations were significant. All significant discordant associations were positive for the two thyroid AIDs, with the exception of Hashimoto thyroiditis with Reiter disease. Overall 8 associations were significant only for Graves disease and 6 Hashimoto thyroiditis. The overall high concordant familial risks for Graves disease and Hashimoto thyroiditis suggest a strong genetic contribution to the familial risk. Significant familial associations among more than half of the 43 AIDs attest to the extensive polyautoimmunity among thyroid AIDs.
000157349 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000157349 588__ $$aDataset connected to CrossRef, PubMed,
000157349 7001_ $$aLi, Xinjun$$b1
000157349 7001_ $$aSundquist, Kristina$$b2
000157349 7001_ $$aSundquist, Jan$$b3
000157349 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b4$$udkfz
000157349 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b5$$eLast author$$udkfz
000157349 773__ $$0PERI:(DE-600)3009706-X$$a10.1016/j.jtauto.2020.100058$$gVol. 3, p. 100058 -$$p100058$$tJournal of translational autoimmunity$$v3$$x2589-9090$$y2020
000157349 909CO $$ooai:inrepo02.dkfz.de:157349$$pVDB
000157349 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000157349 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000157349 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000157349 9141_ $$y2020
000157349 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-18
000157349 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-18
000157349 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-26T13:09:35Z
000157349 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-26T13:09:35Z
000157349 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-01-26T13:09:35Z
000157349 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-18
000157349 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-18
000157349 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2022-11-18
000157349 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-18
000157349 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-18
000157349 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-18
000157349 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-18
000157349 9202_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000157349 9201_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000157349 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000157349 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000157349 9200_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000157349 980__ $$ajournal
000157349 980__ $$aVDB
000157349 980__ $$aI:(DE-He78)C050-20160331
000157349 980__ $$aI:(DE-He78)B062-20160331
000157349 980__ $$aI:(DE-He78)HD01-20160331
000157349 980__ $$aUNRESTRICTED